Light Mode
$2.15 ↓ -0.00 (-0.23%) Trading Down from the previous close of $2.16, $0.07 below the day’s high of $2.22
-0.53 (-19.70%) / 6M
Momentum, market sentiment, and recent alerts
OVID reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +35.0%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Ovid Therapeutics, Inc. is a biopharmaceutical company dedicated to pioneering better, gentler medicines for the brain. It discovers and develops differentiated, small molecule medicines for neurological and neuropsychiatric disorders with significant unmet need. The company was founded by Matthew During and Jeremy M. Levin on April 1, 2014 and is headquartered in New York, NY.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.